Answers are grounded in this paper and cite their sources.
Critical commentary reveals statistical and methodological concerns in cross-over trials for post-COVID syndrome, highlighting the need for cautious interpretation of immunoadsorption efficacy.
We read the paper by Marco Stortz et al.1 which is published in the Journal of the Lancet Regional Health - Europe in June 2026 with great interest. The authors aimed to determine whether autoantibody depletion by immunoadsorption is effective to reduce the symptom burden of patients with post-Covid syndrome, with a cross-over study. Although the results of the study are very interesting, however, it seems that several statistical and methodological issues should be considered when interpreting the results.
No takes yet. Share an insight, caveat, or question.
Mansori et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: